Positive Outlook for Lisata Therapeutics as Analyst Reaffirms Buy Rating Amid Strong Financials and Promising Clinical Trials

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Lisata Therapeutics (LSTA – Research Report), retaining the price target of $15.00.

Joseph Pantginis has given his Buy rating due to a combination of factors indicating a strong future for Lisata Therapeutics. The company’s financial results for the first quarter of 2024 showed a better-than-expected earnings per share, and they maintain a cash position considered sufficient to support their ongoing and proposed clinical trials into early 2026. Furthermore, Lisata’s lead candidate, certepetide, has achieved significant regulatory milestones, such as receiving the Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma. This designation could lead to faster review processes and potential incentives like the Priority Review Voucher, which adds considerable value.

Pantginis’s optimism is also bolstered by the anticipated clinical milestones set for the next 18 months. Multiple clinical studies are advancing, with the Phase 2b ASCEND study in metastatic pancreatic ductal adenocarcinoma having completed enrollment for one of its cohorts, with results expected by the fourth quarter of 2024. The BOLSTER and CENDIFOX trials are progressing as planned, and the study of certepetide in glioblastoma multiforme has started dosing. These developments suggest that Lisata Therapeutics is on a clear path to potential future approvals and the design of a subsequent Phase 3 trial, which further justifies the Buy rating.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Lisata Therapeutics (LSTA) Company Description:

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.